Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

APTO has been the topic of several other research reports. Canaccord Genuity Group lowered their price target on Aptose Biosciences from $15.00 to $6.00 and set a buy rating on the stock in a report on Thursday, May 16th. HC Wainwright reissued a buy rating and issued a $7.00 price target on shares of Aptose Biosciences in a research note on Friday, June 14th. Finally, Piper Sandler restated an overweight rating and set a $5.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $14.83.

Aptose Biosciences Stock Performance

Shares of APTO opened at $0.49 on Thursday. The stock has a market capitalization of $8.86 million, a price-to-earnings ratio of -0.08 and a beta of 1.27. Aptose Biosciences has a 52-week low of $0.47 and a 52-week high of $5.10. The stock’s 50-day simple moving average is $0.78 and its 200 day simple moving average is $1.31.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.09. On average, research analysts forecast that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned about 0.16% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.